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BACKGROUND
Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the pres-
ence of an expanded somatic blood-cell clone in persons without other hematologic 
abnormalities, is common among older persons and is associated with an increased 
risk of hematologic cancer. We previously found preliminary evidence for an association 
between CHIP and atherosclerotic cardiovascular disease, but the nature of this asso-
ciation was unclear.
METHODS
We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood 
cells and associated such presence with coronary heart disease using samples from four 
case–control studies that together enrolled 4726 participants with coronary heart dis-
ease and 3529 controls. To assess causality, we perturbed the function of Tet2, the 
second most commonly mutated gene linked to clonal hematopoiesis, in the hemato-
poietic cells of atherosclerosis-prone mice.
RESULTS
In nested case–control analyses from two prospective cohorts, carriers of CHIP had a 
risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% con-
fidence interval [CI], 1.4 to 2.7). In two retrospective case–control cohorts for the 
evaluation of early-onset myocardial infarction, participants with CHIP had a risk of 
myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). 
Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with 
coronary heart disease. CHIP carriers with these mutations also had increased coro-
nary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholester-
olemia-prone mice that were engrafted with bone marrow obtained from homozygous 
or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root 
and aorta than did mice that had received control bone marrow. Analyses of macro-
phages from Tet2 knockout mice showed elevated expression of several chemokine and 
cytokine genes that contribute to atherosclerosis.
CONCLUSIONS
The presence of CHIP in peripheral-blood cells was associated with nearly a doubling 
in the risk of coronary heart disease in humans and with accelerated atherosclerosis in 
mice. (Funded by the National Institutes of Health and others.)
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Aging is associated with an in-creased incidence of cancer and cardio-vascular disease. We and others recently 
used whole-exome sequencing data to identify a 
common, age-related disorder marked by an ex-
pansion of hematopoietic clones carrying recur-
rent somatic mutations, most frequently loss-of-
function alleles in the genes DNMT3A, TET2, and 
ASXL1.1-3 These mutations, which are also com-
mon in the myelodysplastic syndrome and acute 
myeloid leukemia,4 provide a selective advantage 
to the hematopoietic stem cells in which they 
occur5,6 and are detectable as clones in peripheral-
blood samples because the mutated stem cells 
maintain the ability to differentiate into circulat-
ing granulocytes, monocytes, and lymphocytes.7,8 
Such clones rarely accumulate in persons younger 
than 40 years of age, but they become more com-
mon among older persons, with more than 10% 
of persons older than 70 years of age carrying 
such a mutation. Carriers of these mutations have 
10 times the risk of a hematologic cancer as do 
those without such mutations. On the basis of 
these findings, we provisionally defined persons 
carrying such mutations in the absence of any 
other hematologic abnormalities as having clonal 
hematopoiesis of indeterminate potential (CHIP).9
Our exploratory analysis revealed that persons 
with CHIP are at increased risk for death from 
any cause and, surprisingly, for coronary heart 
disease.1 Although traditional risk factors for 
coronary heart disease (e.g., hypercholesterol-
emia, type 2 diabetes, hypertension, and smok-
ing) account for a large proportion of the risk, 
many persons with atherosclerosis or coronary 
heart disease do not have established risk fac-
tors,10,11 which suggests that unknown factors 
may also contribute to atherosclerosis and its 
complications. In this study, we tested the hy-
pothesis that CHIP contributes causally to athero-
sclerotic cardiovascular disease.
Me thods
Study Samples
The primary samples that we used were ob-
tained from four case–control studies that to-
gether enrolled 4726 participants with coronary 
heart disease and 3529 controls. The protocols 
for all four of these studies were approved by the 
ethics committees at all involved institutions; 
written informed consent was obtained from all 
the participants.
First, we used a modified nested case–control 
study design from two prospective cohort stud-
ies, BioImage and Malmö Diet and Cancer (MDC). 
BioImage was selected because of the enrichment 
of the cohort with older participants at high 
cardiovascular risk,12 whereas MDC was selected 
because of its long follow-up period and extensive 
phenotypic data.13 After the exclusion of partici-
pants with prevalent cardiovascular events, coro-
nary heart disease was defined as a history of 
myocardial infarction or coronary revasculariza-
tion after the time of DNA collection. Among 
these participants, we selected those with coro-
nary heart disease who were matched with con-
trols on the basis of age, sex, type 2 diabetes 
status, and smoking history without regard to 
follow-up time. The baseline characteristics of 
the participants in these two cohorts are shown 
in Table S1 in the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org.
We analyzed whole-exome sequencing data 
from two retrospective case–control studies, the 
Atherosclerosis, Thrombosis, and Vascular Biol-
ogy Italian Study Group (ATVB)14 and the Pakistan 
Risk of Myocardial Infarction Study (PROMIS),15,16 
to evaluate participants with early-onset (age, 
<50 years) myocardial infarction. In these stud-
ies, case participants consisted of those with 
early-onset myocardial infarction who were se-
lected at the time of the index presentation to 
hospitals, and controls were persons from the 
same medical centers who did not have cardio-
vascular disease. In ATVB, case participants 
were 45 years of age or younger and were age-
matched with controls, whereas in PROMIS we 
selected only case participants and controls who 
were from 40 to 50 years of age. The baseline 
characteristics of the participants in these two 
cohorts are shown in Table S2 in the Supplemen-
tary Appendix.
To understand which CHIP genes contributed 
to the risk of coronary heart disease, we per-
formed a gene-level analysis on samples obtained 
from BioImage, MDC, and three prospective 
cohorts unselected for coronary events: the Jack-
son Heart Study (JHS), the Finland–United States 
Investigation of NIDDM [Non–Insulin-Dependent 
Diabetes Mellitus] Genetics (FUSION), and the 
Framingham Heart Study (FHS).17 JHS and FUSION 
were part of our prior association study of CHIP 
with coronary heart disease,1 whereas samples 
from FHS were newly analyzed for this study.
A Quick Take 
is available at 
NEJM.org
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Whole-Exome Sequencing
DNA was obtained from individual studies, and 
further processing was performed at the Broad 
Institute of Harvard and the Massachusetts In-
stitute of Technology. We performed whole-exome 
sequencing on blood samples obtained from 113 
participants with coronary heart disease and 257 
controls from BioImage and on samples obtained 
from 320 participants with coronary heart dis-
ease and 320 controls from MDC. Whole-exome 
sequencing in ATVB and PROMIS had been per-
formed previously. We identified CHIP carriers 
on the basis of a prespecified list of variants in 
74 genes known to be recurrently mutated in 
myeloid cancers (Table S3 in the Supplementary 
Appendix). Details regarding the sequencing pro-
cedures are provided in the Extended Methods 
section in the Supplementary Appendix.
Atherosclerosis in Mice
We transplanted atherosclerosis-prone mice that 
were bred to have a knockout mutation for the 
gene encoding low-density lipoprotein receptor 
(Ldlr) with bone marrow from Tet2 control mice 
or heterozygous or homozygous knockout mice. 
The mice were started on a high-fat, high-choles-
terol diet and then assessed for atherosclerosis at 
various time points. We performed gene-expres-
sion analysis on macrophages cultured from bone 
marrow obtained from Tet2 control or knockout 
mice that had been exposed to vehicle or low-
density lipoprotein (LDL).
Statistical Analysis
In the analysis of data from the BioImage and 
MDC studies, we used a Cox proportional-haz-
ards model after adjustment for age, sex, type 2 
diabetes status, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, hypertension, and 
smoking status. In the analysis of data from 
ATVB and PROMIS, we analyzed whole-exome 
sequencing data using a logistic-regression model 
after adjustment for age, sex, type 2 diabetes 
status, and smoking status. Details regarding the 
statistical analysis are provided in the Extended 
Methods section in the Supplementary Appendix.
R esult s
Association between CHIP and Coronary 
Heart Disease
In the samples obtained from the BioImage and 
MDC studies, we found that the somatic mutations 
most commonly occurred in the genes DNMT3A, 
TET2, and ASXL1 and that 72 of 77 participants 
(94%) with CHIP had a mutation in only a single 
driver gene1,2 (Table S4 and Fig. S1 in the Supple-
mentary Appendix).
The median age of the participants in BioImage 
at the time of DNA sample collection was 70 years, 
and the median follow-up time was 2.6 years. 
We found that 19 of 113 participants with coro-
nary heart disease (17%) were CHIP carriers ver-
sus 25 of 257 controls (10%) (hazard ratio, 1.8; 
95% confidence interval [CI], 1.1 to 2.9; P = 0.03). 
The median age of the participants in MDC was 
60 years at the time of DNA sample collection, 
and the median follow-up was 17.7 years. CHIP 
was identified in 21 of 320 participants with 
coronary heart disease (7%) versus in 12 of 320 
controls (4%) (hazard ratio, 2.0; 95% CI, 1.2 to 
3.1; P = 0.003) (Fig. 1A, and Table S5 and Fig. S2 
in the Supplementary Appendix). The combined 
analysis of the two cohorts in a fixed-effects 
meta-analysis showed that the CHIP carriers had 
a risk of incident coronary heart disease that was 
1.9 times as great as in noncarriers (95% CI, 1.4 
to 2.7; P<0.001).
Association between CHIP and Early-Onset 
Myocardial Infarction
In both ATVB and PROMIS, participants with 
early-onset myocardial infarction had marked 
enrichment of CHIP, as compared with controls. 
In ATVB, 37 of 1753 participants with myocardial 
infarction (2%) were CHIP carriers versus 6 of 
1583 controls (<1%) (odds ratio, 5.4; 95% CI, 2.3 
to 13.0; P<0.001). In PROMIS, 52 of 2540 partici-
pants with myocardial infarction (2%) were CHIP 
carriers versus 13 of 1369 controls (1%) (odds 
ratio, 3.4; 95% CI, 1.8 to 6.5; P<0.001). A com-
bined fixed-effects meta-analysis of these two 
cohorts showed that CHIP was associated with 
an odds ratio of 4.0 (95% CI, 2.4 to 6.7; P<0.001) 
for early-onset myocardial infarction (Fig. 1B).
Association between Risk Mutations  
and Coronary Events
In samples obtained from BioImage, MDC, and 
the three prospective cohorts unselected for coro-
nary events, we specifically tested for associations 
between coronary heart disease and mutations in 
DNMT3A, TET2, ASXL1, and JAK2. Participants 
with mutations in DNMT3A, TET2, and ASXL1 had 
1.7 to 2.0 times the risk of incident coronary 
heart disease as did those with no mutations, 
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whereas the JAK2 V617F mutation was associated 
with 12.1 times the risk (Fig. 2A).
Mutations in TET2, JAK2, and ASXL1 also 
showed significant enrichment among participants 
with early-onset myocardial infarction in samples 
obtained from ATVB and PROMIS, with myocar-
dial infarction identified in 12 of 13 participants 
with TET2 mutations, in 8 of 8 participants with 
ASXL1 mutations, and in 16 of 16 participants with 
JAK2 mutations (Fig. 2B). JAK2 V617F accounted 
for 19% of the total mutations among patients 
with myocardial infarction in ATVB and PROMIS 
but for only 4% in BioImage and MDC (Fig. 2C).
Association between CHIP and Coronary-
Artery Calcification
We hypothesized that an increased atherosclero-
sis burden drives the association between CHIP 
and coronary heart disease, rather than other 
factors that might cause myocardial infarction, 
such as increased thrombosis or vasospasm. 
Among the participants in the BioImage study, 
we assessed data on coronary-artery calcification, 
a noninvasive measure of atherosclerosis as de-
tected on cardiac computed tomography. Among 
those without incident coronary heart disease, 
CHIP carriers had a median score for coronary-
Figure 1. Association between Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Coronary Heart Disease 
and Early-Onset Myocardial Infarction.
Panel A shows a forest plot of hazard ratios for the association between coronary heart disease and CHIP in the 
BioImage and Malmö Diet and Cancer (MDC) studies. Hazard ratios for coronary heart disease among study par­
ticipants with CHIP mutations were obtained with the use of a Cox proportional­hazards model after adjustment  
for age, sex, type 2 diabetes status, total cholesterol, high­density lipoprotein (HDL) cholesterol, smoking status, 
and hypertension. Panel B shows a forest plot of odds ratios for the association between myocardial infarction and 
CHIP in the Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group (ATVB) and the Pakistan Risk of 
Myocardial Infarction Study (PROMIS). The odds ratios were obtained with the use of a logistic­regression model 
after adjustment for age, sex, type 2 diabetes status, and smoking status.
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artery calcification that was 3.3 times as high as 
that in noncarriers (306 versus 92 Agatston 
units); in those with incident coronary heart 
disease, the score was 1.8 times as high in CHIP 
carriers as in noncarriers (650 versus 355 Agat-
ston units) (P = 0.03 by linear regression after 
adjustment for incident coronary heart disease) 
(Fig. 3A).
A coronary-artery calcification score of 615 
Agatston units or more has served as an empiri-
cal cutoff for identifying older persons at high 
risk for coronary events.18 Among the partici-
pants without incident coronary heart disease, 
CHIP carriers were 3.0 times as likely to have a 
coronary-artery calcification score of 615 or more 
than were noncarriers (P = 0.05 by logistic regres-
sion after adjustment for age, sex, type 2 diabe-
tes status, total cholesterol, HDL cholesterol, 
hypertension, and smoking status) (Fig. 3B).
We had previously found that the presence of 
a CHIP clone with a variant allele fraction of at 
least 10% (which corresponds to ≥20% of nucle-
ated blood cells harboring the mutation) was 
associated with a greater risk of a hematologic 
cancer than a CHIP clone below this size.1 There-
fore, we tested whether CHIP with a larger clone 
size was also associated with a greater burden of 
atherosclerosis. CHIP carriers without incident 
coronary heart disease but with a variant allele 
fraction of a least 10% had 12 times the risk of 
having a coronary-artery calcification score of 615 
or more as did noncarriers (P = 0.002 by logistic 
regression after adjustment), whereas participants 
with a variant allele fraction of less than 10% 
had no increased risk (P = 0.02 for heterogeneity) 
(Fig. 3B, and Fig. S3 in the Supplementary Ap-
pendix).
We hypothesized that the participants with 
an increased proportion of mutated cells might 
also have a greater risk of incident coronary 
heart disease. In a meta-analysis of data from 
BioImage and the three prospective cohorts un-
selected for coronary events, we found that the 
risk of incident coronary heart disease was 2.2 
times as great among the participants with a 
variant allele fraction of at least 10% as among 
those without mutations (P<0.001 by Cox pro-
portional hazards after adjustment), whereas 
those with a variant allele fraction of less than 
10% had a risk that was 1.4 times as great 
(P = 0.16; P = 0.24 for heterogeneity) (Fig. S4 in 
the Supplementary Appendix). In this analysis, 
data from MDC were not included because DNA 
in this cohort was obtained from granulocytes 
rather than whole blood, which would probably 
inflate the variant allele fraction.
Figure 3. Association between CHIP and Increased Coronary-Artery 
 Calcification.
Panel A shows coronary­artery calcification (CAC) scores in Agatston units 
among participants with CHIP and those without CHIP in the BioImage 
study, stratified according to the presence or absence of incident coronary 
heart disease. The horizontal line in each box indicates the median score, 
and the top and bottom of the boxes indicate the 75th and 25th percen­
tiles, respectively. Among the participants with no coronary heart disease, 
the median scores were 92 for no CHIP and 306 for CHIP; among those 
with coronary heart disease, the median scores were 355 and 650, respec­
tively. P = 0.03 for the comparison between CHIP and no CHIP; the P value 
was obtained with the use of a linear­regression model of logarithm­trans­
formed CAC plus 1, after adjustment for incident coronary heart disease 
status. Panel B shows a forest plot of odds ratios for the association be­
tween a CAC score of 615 or more and mutation status, stratified accord­
ing to the variant allele fraction (VAF) among participants with incident 
coronary heart disease in BioImage. The odds ratios were obtained with 
the use of a logistic­regression model after adjustment for age, sex, type 2 
 diabetes status, total cholesterol, HDL cholesterol, smoking status, and 
 hypertension. P = 0.02 for heterogeneity between a VAF of less than 0.10 
and a VAF of 0.10 or more.
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Tet2 Knockout Mice and Accelerated 
Atherosclerosis
Having established a correlation between CHIP 
and coronary heart disease, we next sought to 
assess causality experimentally. We selected Tet2 
for further study because it is the second most 
commonly mutated gene in CHIP and has been 
associated with the risk of coronary heart dis-
ease regardless of age. In previous studies, hema-
topoietic stem cells from mice that are homo-
zygous for loss of function of Tet2 in all 
hematopoietic cells recapitulate the clonal advan-
tage of mutated TET2 hematopoietic cells seen in 
humans.6
We transplanted bone marrow from these 
mice and from control mice into irradiated, 
atherosclerosis-prone Ldlr knockout mice19 and 
initiated a high-cholesterol diet after allowing 
time for hematopoietic reconstitution. As com-
pared with mice that had received control bone 
marrow, mice that had received bone marrow 
from the Tet2 knockout mice had a median lesion 
size in the aortic root that was 2.0 times as large 
after 5 weeks (P = 0.02 by the Wilcoxon rank-sum 
test), that was 1.7 times as large after 9 weeks 
(P = 0.01 by the Wilcoxon rank-sum test), and that 
was 1.4 times as large after 13 weeks (P = 0.03 by 
Dunn’s test) (Fig. 4A and 4B, and Fig. S5A and 
S5B in the Supplementary Appendix). By 17 weeks, 
the median lesion size in the descending aorta 
was 2.7 times as large in the mice that had re-
ceived bone marrow from Tet2 knockout mice as 
in those that had received control bone marrow 
(P = 0.02 by Dunn’s test) (Fig. 4C and 4D).
Most humans with TET2-associated CHIP 
have a mutation in only a single allele of the 
gene.1,2 Therefore, we also tested the phenotype 
of Tet2 haploinsufficiency. Ldlr knockout mice 
receiving bone marrow from mice that were 
heterozygous for the Tet2 deletion had a median 
aortic-root lesion size that was 1.4 times as large 
as that in control mice after 13 weeks on the 
high-cholesterol diet (P = 0.05 by Dunn’s test) 
(Fig. S5A and S5B in the Supplementary Appen-
dix); after 17 weeks, the median lesion size in 
the descending aorta was 2.7 times as large 
(P = 0.03 by Dunn’s test) (Fig. 4C and 4D).
Mice receiving bone marrow from Tet2 knock-
out mice had normal levels of peripheral-blood 
white cells and a normal differential count dur-
ing the study period. There also was no signifi-
cant between-group difference in fasting serum 
lipid levels after 17 weeks on the high-cholesterol 
diet (Table S6 in the Supplementary Appendix).
Loss of Tet2 Function in Myeloid Cells
The earliest stages of atherosclerosis involve mono-
cyte infiltration into vessel walls and differentia-
tion into macrophages.20 We hypothesized that 
Tet2 loss alters the function of macrophages 
(and their precursor monocytes) in plaques to 
enhance atherosclerosis. We tested this hypothe-
sis by generating mice that lacked Tet2 in the ma-
jority of myeloid cells but not in other lineages; to 
create this murine line, we bred mice with loxP 
sites flanking exon 3 of Tet2 with mice that ex-
press Cre recombinase from the Lyz2 promoter.21 
In Ldlr knockout mice that had received bone 
marrow from these mice, the mean size of the 
aortic-root lesion was 1.7 times as large as in 
mice that had received control bone marrow after 
10 weeks on the high-cholesterol diet (P = 0.003 
by the Wilcoxon rank-sum test) (Fig. S5C in the 
Supplementary Appendix).
Tet2 catalyzes DNA hydroxymethylation,22 an 
epigenetic modification that can influence gene 
transcription. Therefore, we hypothesized that 
Tet2 modulated gene expression in macrophages 
exposed to excess cholesterol. We cultured bone 
marrow–derived macrophages from Tet2 knock-
out or control mice, incubated them with either 
vehicle or a pathophysiologically relevant dose of 
native LDL (200 mg per deciliter),23,24 and ana-
lyzed the transcriptome using messenger RNA 
sequencing. Gene set enrichment analysis re-
vealed that the most significantly up-regulated 
functional class of genes in Tet2 knockout macro-
phages contained cytokines or chemokines and 
receptors, whereas the most significantly sup-
pressed class contained genes involved in lyso-
somal function. Gene class annotations were 
obtained from the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database (Tables S7 and 
S8 and Fig. S6 in the Supplementary Appendix).
We focused on the set of 217 genes that 
showed differential regulation by both loss of 
Tet2 and by LDL treatment. Transcript levels in 
Cxcl1, Cxcl2, Cxcl3, Pf4, Il1b, and Il6 were among 
the most highly induced in Tet2 knockout mac-
rophages in this set (Fig. S7A and S7B in the 
Supplementary Appendix). Cxcl1, Cxcl2, Cxcl3, and 
Pf4 belong to a single C-X-C motif (CXC) chemo-
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kine gene cluster, whereas Il1b and Il6 are classic 
proinflammatory cytokine genes. Tet2 knockout 
macrophages also secreted more of these pro-
teins in vitro in response to LDL loading or en-
dotoxin exposure than did control macrophages. 
Although either LDL or endotoxin strongly in-
duced the CXC chemokines, endotoxin but not 
LDL caused robust secretion of interleukin-1b 
and interleukin-6 (Fig. S7C in the Supplementary 
Appendix).
To assess the in vivo importance of these ob-
servations, we measured CXC chemokine levels 
in the transplanted mice after they had been on 
an atherogenic diet for 13 to 17 weeks. We found 
that the levels of Cxcl1, Cxcl2, Cxcl3, Pf4, and 
Ppbp were 2 to 4 times as high in the serum of 
mice that had received bone marrow from Tet2 
knockout mice as in mice that had received con-
trol bone marrow, whereas those that had received 
bone marrow from mice that were heterozygous 
Figure 4. Loss of Tet2 in Hematopoietic Cells and Atherosclerosis in a Murine Model.
Shown are the effects of the transplantation of bone marrow into female, atherosclerosis­prone Ldlr knockout mice, 
according to whether the donor mice had wild­type (WT) Tet2, heterozygous (HET) Tet2, or knockout (KO) Tet2. 
Deletions in Tet2 were obtained by using Cre recombinase expressed from the Vav1 promoter. Panel A shows aortic­
root sections obtained from mice that had received transplants from WT or KO Tet2 mice after the mice had received 
a high­cholesterol diet for 5 weeks and 9 weeks (oil red O staining at 5 weeks and Masson’s trichrome staining at 
9 weeks). The dashed lines indicate the lesion areas. Panel B shows the quantification of aortic­root lesions in mice 
that had received transplants from WT or KO Tet2 mice at 5 weeks and 9 weeks. P values were obtained with the use 
of the Wilcoxon rank­sum test. Panel C shows lesions in the descending aorta that were stained with oil red O at 17 
weeks in mice that had received transplants from WT, HET, or KO Tet2 mice. The amount of red dye that is visible 
indicates the degree of atherosclerosis, according to Tet2 status. Panel D shows the quantification of lesions in the 
descending aorta at 17 weeks, according to Tet2 status. P values were obtained with the use of Dunn’s Kruskal–Wallis 
test for multiple comparisons and the Benjamini–Hochberg correction. In Panels B and D, the black horizontal lines 
represent the median values.
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for Tet2 deletion showed intermediate levels (Fig. 
S7D in the Supplementary Appendix).
We also sought evidence of increased inflam-
mation in other tissues. In mice that had re-
ceived Tet2 knockout bone marrow, there was 
development of prominent xanthomas in the 
spleen and middle ear, marked foam-cell accu-
mulation and glomerulosclerosis in the kidney, 
and large inflammatory infiltrates in the liver 
and lung (Fig. S8A and S8B in the Supplemen-
tary Appendix).
Because we found increased levels of CXC 
chemokines in the serum of mice that had re-
ceived bone marrow from Tet2 knockout mice, 
we tested for an analogous increase in humans 
with TET2 clonal hematopoiesis. The prototypi-
cal CXC chemokine in humans is interleukin-8, 
which mice lack. Plasma levels of interleukin-8 
were available from 2689 controls (age range, 40 to 
82 years) in the PROMIS study. The 12 partici-
pants with TET2 mutations in this cohort had 
significantly higher circulating interleukin-8 levels 
than did those without the mutations (median 
level, 50 vs. 21 ng per milliliter; P = 0.02 by the 
Wilcoxon rank-sum test on log-transformed val-
ues) (Fig. S8C in the Supplementary Appendix).
Discussion
In four distinct studies involving human partici-
pants, we found that somatic mutations leading 
to CHIP had significant associations with the risk 
of coronary heart disease or early-onset myocar-
dial infarction. In a murine model of atheroscle-
rosis, the loss of Tet2 function in hematopoietic 
cells accelerated atherogenesis.
These results support several conclusions. First, 
the relationship between CHIP and coronary 
heart disease appears to be a causal one. Experi-
mental manipulation of one of the genes that is 
most frequently mutated in CHIP — Tet2 — 
worsened atherosclerosis in mice. In humans, 
coronary events increased in relation to clone 
size, and there was also a dose–response rela-
tionship between clone size and atherosclerosis 
on imaging.
Second, mutations in multiple CHIP-associated 
genes were linked to coronary heart disease. 
We suggest that these mutations may increase 
the risk of coronary events owing to altered tran-
scriptional output of macrophages. These cells 
mediate many inflammatory responses and prom-
inently populate atherosclerotic plaques.25,26 In 
support of this model, we found that loss of Tet2 
augmented the expression of inflammatory chemo-
kines in macrophages that were exposed to na-
tive LDL, an effect that is similar to that in 
Tet2-deficient macrophages that were exposed to 
bacterial endotoxin.27
Previous studies have shown that CXC chemo-
kine interaction with the receptor CXCR2 can 
mediate firm monocyte adhesion to inflamed 
endothelium28,29 and that this interaction promotes 
atherogenesis.30,31 We propose that a major con-
sequence of TET2 deficiency in tissue macro-
phages is the enhanced recruitment of mono-
cytes and other blood cells to peripheral sites, 
including the arterial intima, because of elevated 
expression of CXC chemokines. Several organs of 
mice lacking hematopoietic Tet2 harbored large 
leukocyte aggregates, and TET2 mutations in 
humans were associated with increased plasma 
levels of interleukin-8. A recent study also identi-
fied augmented Il1b and inflammasome activa-
tion as a major mediator of atherosclerosis in mice 
with hematopoietic Tet2 deficiency.32 It is unclear 
which particular inflammatory mediators pre-
dominate in driving atherosclerosis associated 
with TET2 deficiency and whether mutations in 
DNMT3A, ASXL1, and JAK2 also influence the risk of 
coronary events by means of increased inflamma-
tion, issues that invite further experimentation.
An alternative explanation for the observed 
association is that CHIP-associated mutations 
provide a proliferative advantage to hematopoietic 
progenitors and a consequent increase in cir-
culating myeloid cells. Elevations in levels of 
peripheral-blood granulocytes and monocytes have 
been linked to coronary outcomes in the general 
population,33 whereas persons with JAK2-mutated 
myeloproliferative neoplasms are at increased risk 
for venous and coronary thrombosis, according 
to the degree of leukocytosis.34,35 However, nearly 
all persons with clonal hematopoiesis caused by 
mutations in DNMT3A, TET2, and ASXL1 have a 
normal white-cell count and differential,1,36 and 
JAK2 mutations account for only a small percent-
age of CHIP. Furthermore, mice that lacked hema-
topoietic Tet2 had normal blood counts in our 
study and in previous studies.32,37 Nonetheless, 
we cannot fully rule out a role for leukocytosis 
in human coronary heart disease, since CHIP 
could lead to a myeloproliferative state over sev-
eral years.
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In conclusion, our data support the hypothe-
sis that somatic mutations in hematopoietic cells 
contribute to the development of human athero-
sclerosis. We propose that clonal hematopoiesis 
may be a modifiable risk factor, perhaps through 
the use of cholesterol-lowering medications or 
targeting of specific inflammatory pathways.
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